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Abstract 43 
The spreading of multidrug-resistant Candida auris is considered as an emerging global 44 
health threat. The number of effective therapeutic regimens is strongly limited; therefore, 45 
development of novel strategies is needed. Farnesol is a quorum-sensing molecule with a 46 
potential antifungal and/or adjuvant effect; it may be a promising candidate in alternative 47 
treatment against Candida species including C. auris. To examine the effect of farnesol on C. 48 
auris, we performed experiments focusing on growth, biofilm production ability, production 49 
of enzymes related to oxidative stress, triazole susceptibility and virulence. Concentrations 50 
ranging from 100 to 300 M farnesol caused a significant growth inhibition against C. auris 51 
planktonic cells for 24 hours (p<0.01-0.05). Farnesol treatment showed a concentration 52 
dependent inhibition in terms of biofilm forming ability of C. auris; however, it did not 53 
inhibit significantly the biofilm development at 24 hours. Nevertheless, the metabolic activity 54 
of adhered farnesol pre-exposed cells (75 M) was significantly diminished at 24 hours 55 
depending on farnesol treatment during biofilm formation (p<0.001-0.05). Moreover, 300 M 56 
farnesol exerted a marked decrease in metabolic activity against one-day-old biofilms 57 
between 2 and 24 hours (p<0.001). Farnesol increased the production of reactive species 58 
remarkably, as revealed by 2’,7’-dichlorofluorescein (DCF) assay (3.96±0.89 [nmol DCF 59 
(OD640)
-1] and 23.54±4.51 [nmol DCF (OD640)
-1] for untreated cells and farnesol exposed 60 
cells, respectively; p<0.001). This was in line with increased superoxide dismutase level 61 
(85.69±5.42 [munit (mg protein)-1] and 170.11±17.37 [munit (mg protein)-1] for untreated 62 
cells and farnesol exposed cells, respectively; p<0.001), but the catalase level remained 63 
statistically comparable between treated and untreated cells (p>0.05). Concerning virulence-64 
related enzymes, exposure to 75 M farnesol did not influence phospholipase or aspartic 65 
proteinase activity (p>0.05). The interaction between fluconazole, itraconazole, voriconazole, 66 
posaconazole, isavuconazole and farnesol showed clear synergism (FICI ranges from 0.038 to 67 
0.375) against one-day-old biofilms. Regarding in vivo experiments, daily 75 M farnesol 68 
treatment decreased the fungal burden in an immuncompromised murine model of 69 
disseminated candidiasis, especially in case of inocula pre-exposed to farnesol (p<0.01). In 70 
summary, farnesol shows a promising therapeutic or adjuvant potential in traditional or 71 
alternative therapies such as catheter lock therapy. 72 
 73 
Contribution to the field 74 
To date Candida auris had been reported from more than 35 countries on six different 75 
continents. This newly emerged multidrug-resistant fungal pathogen causes nosocomial 76 
outbreaks with high crude mortality rate. The number of resistant isolates to all of three main 77 
classes of antifungals is steadily increasing worldwide. Due to the alarming emergence of 78 
antifungal resistance, there is an urgent need to develop alternative antifungal therapies. An 79 
attractive novel approach to combating fungal infections caused by multi-resistant pathogens 80 
is treatments targeting quorum-sensing. Farnesol was the first described fungal quorum-81 
sensing molecule, causing hyphae-to-yeast transition in C. albicans. However, it is 82 
noteworthy that farnesol may act differently in non-albicans Candida species; in addition, it 83 
may have potent synergizing and/or antifungal effect. In this study, we performed 84 
investigations focusing on growth, biofilm production ability, oxidative stress related enzyme 85 
production, azole susceptibility and virulence in order to examine the effect of farnesol 86 
exposure on C. auris. Based on our results, farnesol has an inhibitory effect both against 87 
planktonic cells and biofilms. In addition, it showed a remarkable therapeutic potential in our 88 
systemic immunocompromised mouse model. These results may support the development of 89 
novel alternative therapies against C. auris infections in the future.  90 
 91 
 92 
 93 
94 
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1. Introduction 95 
Candida auris is an emerging fungal pathogen causing outbreaks in healthcare settings with 96 
unacceptably high mortality rates ranging from 28% to 78% depending on the country 97 
(Jeffrey-Smith et al. 2018, Eyre et al. 2018). To date, 39 countries have reported C. auris 98 
associated infections (Jeffrey-Smith et al. 2018, Eyre et al. 2018, Kean et al. 2020). Based on 99 
last published data, the number of confirmed C. auris infections were 620 and 988 in Europe 100 
and United States of America, respectively (CDC 2019, ECDC 2018). Nosocomial C. auris 101 
outbreaks were reported from several countries including India, South Africa, Venezuela, 102 
Pakistan, and the United States (Vallabhaneni et al. 2016, Lockhart et al. 2017, Belkin et al. 103 
2018). Previously, genetic analyses revealed more genetically unrelated clonal populations 104 
across three different continents. These clades are commonly classified as South African, 105 
South Asian, East Asian and South American clades (Lockhart et al. 2017). In addition, a 106 
recent study described a fifth C. auris clade in Iran from patient who never travelled outside 107 
that country (Abastabar et al. 2019, Chow et al. 2019). 108 
Over 90% of clinical isolates are resistant to fluconazole whereas resistance to newer triazoles 109 
is variable (Dudiuk et al 2019, Romera et al 2019). The ratio of strains resistant to 110 
amphotericin B ranges from 8% to 50%, while echinocandin resistance remains infrequent 111 
(2% to 8%) (Dudiuk et al 2019). Alarmingly, isolates of C. auris with resistance to all three 112 
major antifungal classes have been reported in multiple countries including the USA 113 
(Ostrowsky et al. 2020). These multidrug-resistant strains may remain susceptible to nystatin 114 
and terbinafine (Sarma and Upadhyay 2017). C. auris biology have been extensively covered 115 
in recent papers (Rossato and Colombo 2018, Casadevall et al. 2019), however, the data about 116 
potential alternative treatment strategies remain scarce (Wall et al. 2019); therefore, there is 117 
an urgent need for the development of new antifungal therapies. In addition, multidrug-118 
resistance is significantly more frequently reported in the case of C. auris biofilms (Kean and 119 
Ramage 2019). Thus, although the capacity to form biofilms is strain dependent in C. auris, 120 
they frequently pose a remarkable therapeutic challenge, especially because C. auris biofilms 121 
also have a considerable virulence capacity (Kean and Ramage 2019). Since data collected 122 
with C. albicans biofilms cannot be extrapolated to C. auris directly, such studies are urgently 123 
needed to meet this novel challenge (Kean and Ramage 2019). 124 
Farnesol is a fungal quorum-sensing molecule that inhibits yeast-to-hyphae transition and 125 
promotes reverse morphogenesis in C. albicans (Hornby et al. 2001). Based on recent studies, 126 
farnesol acts synergistically with several antifungal agents against C. albicans, C. glabrata, C. 127 
tropicalis as well as against C. parapsilosis planktonic cells and/or biofilms (Katragkou et al. 128 
2015, Kovács et al. 2016, Monteiro et al. 2017, Agustín et al. 2019), thus it has been proposed 129 
as a potential adjuvant therapeutic agent. In addition, its therapeutic potential has already been 130 
confirmed against C. albicans in murine models of mucosal infection (Hisajima et al. 2008, 131 
Bozó et al. 2016). Although farnesol is not beneficial in systemic infections caused by C. 132 
albicans (Navarthna et al. 2007), those data cannot necessarily be extrapolated to non-133 
albicans species including C. auris (Semreen et al. 2019).  134 
This study examines the effect of farnesol exposure on growth, biofilm production, oxidative 135 
stress-related enzyme production, triazole susceptibility and virulence of C. auris, in order to 136 
explore the background of the previously observed antifungal effect. 137 
138 
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2. Materials and methods 139 
 140 
2.1. Organisms  141 
Three C. auris isolates (isolates 10, 12, and 27) obtained from National Mycology Reference 142 
Laboratory, United Kingdom were used together with the SC5314 C. albicans reference 143 
strain. All three C. auris strains derived from the South Asian/Indian lineage (Borman et al. 144 
2017). All C. auris isolates tested showed non-aggregating phenotype, which exhibit 145 
comparable pathogenicity to that of C. albicans (Borman et al. 2016). 146 
 147 
2.2. Toxicity experiments 148 
Ten μM, 50 μM, 150 μM and 300 μM farnesol were evaluated in terms of toxicity to the 149 
Caco-2 cell line using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 150 
(MTT) assay (Sigma, Budapest, Hungary) (Berridge et al. 2005). No toxicity was observed 151 
with any concentration of farnesol.  152 
 153 
2.3. Growth related experiments for planktonic cells 154 
The effect of pre-exposure and continuous farnesol treatment on C. auris and C. albicans 155 
planktonic cells was tested in RPMI-1640 (with L-glutamine and without bicarbonate, pH 7.0 156 
with MOPS; Sigma, Budapest, Hungary) in two experimental settings: i) effect of various 157 
farnesol concentrations against planktonic cells, ii) effect of various farnesol concentrations 158 
against planktonic cells pre-exposed with farnesol (75 μM) for 24-hours. Seventy-five μM 159 
farnesol was chosen as pre-exposure concentration because it corresponds to approximately 160 
double the amount of physiological farnesol production of C. albicans (Weber et al. 2008). 161 
Farnesol was obtained as 3M stock solution, which was diluted to a 30 mM working stock 162 
solution in 100% methanol. The working concentrations of farnesol were prepared in RPMI-163 
1640 medium. Drug-free control was supplemented with 1% (vol/vol) methanol (Kovács et al. 164 
2016, Bozó et al. 2016, Nagy et al. 2019). Farnesol concentrations tested were 10, 50, 100, 165 
300 μM in all experiments.  166 
Living cell number of planktonic cells was determined using time-kill experiments (Kovács et 167 
al. 2014, Kovács et al. 2017). Briefly, samples (100 L) were removed at 0, 2, 4, 6, 8, 10, 12 168 
and 24 hours, serially diluted tenfold, plated (4 x 30 L) onto Sabouraud dextrose agar and 169 
incubated at 35 ºC for 48 hours. All isolates were tested in three independent experiments and 170 
the mean of the three values was used in the analysis. At given time points, one-way ANOVA 171 
with Dunnett’s post-testing was used to analyze the effect on living cell number exerted by 172 
different farnesol concentrations compared to untreated control. 173 
 174 
2.4. Evaluation of extracellular phospholipase and aspartic proteinase activities exerted 175 
by farnesol exposure 176 
Extracellular phospholipase production by farnesol-exposed (75 μM) and untreated C. auris 177 
and C. albicans cells was examined on egg yolk medium (5.85% [wt/vol] NaCl, 0.05% 178 
[wt/vol] CaCl2, and 10% [vol/vol] sterile egg yolk [Sigma, Budapest, Hungary]). Aspartic 179 
proteinase activity was evaluated on solid medium supplemented with bovine serum albumin 180 
(0.02% [wt/vol] MgSO4×7H2O, 0.25% [wt/vol] K2HPO4, 0.5% [wt/vol] NaCl, 0,1% [wt/vol] 181 
yeast extract, 2% [wt/vol] glucose and 0.25% [wt/vol] bovine serum albumin [Sigma, 182 
Budapest, Hungary] agar medium). In case of both assay, 5 μL suspensions of 1 x 107 183 
cells/mL were inoculated onto agar plates as described previously (Kantarcioglu and Yücel 184 
2002). Colony diameters and precipitation zones (Pz) were measured after 7 days of 185 
incubation at 35 °C (Price et al. 1982). Enzyme activities were measured in three independent 186 
experiments for each isolate and are presented as means ± standard deviations. Statistical 187 
analysis of reactive species and enzyme production data were performed by paired Student’s t 188 
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test using GraphPad Prism 6.05 software. The differences between values for treated and 189 
control cells were considered significant if the p value was < 0.05. 190 
 191 
2.5. Reactive species production and antioxidant enzyme activities exerted by farnesol 192 
exposure 193 
Reactive species were measured in the presence or absence of one-day farnesol (75 M) 194 
exposure in RPMI-1640 by a reaction that converts 2’,7’-dichlorofluorescin diacetate to 2’,7’-195 
dichlorofluorescein (DCF) (Sigma, Budapest, Hungary) (Jakab et al. 2015, Jakab et al. 2019). 196 
The amount of DCF produced is proportional to the quantity of reactive species. Catalase and 197 
superoxide dismutase activities were determined as described previously by Jakab et al. 198 
(2015) and Jakab et al. (2019). Reactive species and enzyme activities were measured in three 199 
independent experiments for each isolate and are presented as means ± standard deviations. 200 
Statistical comparisons of reactive species and enzyme production data were performed by 201 
paired Student’s t test using GraphPad Prism 6.05 software. The differences between values 202 
for treated and control cells were considered significant if the p value was < 0.05. 203 
 204 
2.6. Susceptibility testing of planktonic cells to azoles and farnesol 205 
Antifungal susceptibility of C. auris isolates to fluconazole, itraconazole, voriconazole, 206 
posaconazole, isavuconazole and to farnesol (all from Sigma, Budapest, Hungary) was tested 207 
using the broth microdilution method in RPMI-1640 in line with the CLSI standard M27-A3 208 
guideline (Clinical and Laboratory Standards Institute, 2008). The final concentrations of the 209 
drug ranged between 0.5-32 mg/L, 0.008-0.5 mg/L and 1.17-300 μM mg/L for fluconazole, 210 
other tested azoles and farnesol, respectively. Susceptibility testing for planktonic cells was 211 
performed in 96-well microtitre plates at 35 °C for 24 hours. The inoculum was 0.5-2.5x103 212 
cells/mL. Minimum inhibitory concentrations (MICs) were defined as at least 50% growth 213 
reduction compared with untreated control. All isolates were tested in three independent 214 
experiments and the median of the three values was used in the analysis. 215 
 216 
2.7. Biofilm formation 217 
Candida isolates were suspended in RPMI-1640 broth at a concentration of 1x106 cells/mL 218 
and aliquots of 100 µl were inoculated onto flat-bottom 96-well sterile microtitre plates (TPP, 219 
Trasadingen, Switzerland) and then incubated statically at 35 °C for 24 hours to produce one-220 
day-old biofilms (Pierce et al. 2008, Kovács et al. 2016). 221 
 222 
2.8. Metabolic activity changes of biofilms over time following farnesol exposure 223 
The effect of pre-exposure and continuous farnesol treatment on C. auris and C. albicans 224 
biofilms was tested in three experimental settings: i) continuous farnesol treatment for 24-225 
hours during biofilm formation, ii) biofilm forming ability of cells pre-exposed with farnesol 226 
(75 μM) for 24-hours prior to biofilm formation then continuously treated to given farnesol 227 
concentrations for 24-hours during biofilm development, iii) effect of farnesol on one-day-old 228 
biofilms. Farnesol concentrations tested were 10, 50, 100, 300 μM in all experiments. 229 
Metabolic activity of sessile cells was determined at 0, 2, 4, 6, 8, 10, 12 and 24 hours using 230 
XTT-reduction assay (Hawser 1996, Katragkou et al. 2015). All isolates were tested in three 231 
independent experiments and the mean of the three values was used in the analysis. At given 232 
time points, one-way ANOVA with Dunnett’s post-testing was used to analyze the metabolic 233 
activity change exerted by different farnesol concentrations compared to untreated control. 234 
The differences between values for treated and control cells were considered significant if the 235 
p value was lower than 0.05. 236 
 237 
2.9. Susceptibility testing of biofilms 238 
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The activity of triazoles and farnesol against one-day-old biofilms was evaluated using the 239 
XTT-assay (Hawser, 1996, Katragkou et al. 2014, Kovács et al. 2016, Nagy et al. 2019). The 240 
concentrations tested in biofilm MIC determination ranged between 8-512 mg/L, 0.5-32 241 
mg/L, 0.125-8 mg/L and 1.17-300 μM for fluconazole, voriconazole/itraconazole, 242 
posaconazole/isavuconazole and farnesol, respectively. To determine the 24-hour biofilm 243 
MICs, one-day-old biofilms were first washed three times with 200 μL sterile physiological 244 
saline. All wells were filled with 100 μL of 0.5 g/L XTT / 1 μM menadione solution. The 245 
plates were covered and incubated at 35 °C for 2 hours; afterwards, 80 μL of the supernatant 246 
was removed and transferred into a new sterile 96-well plate to measure the absorbance 247 
spectrophotometrically at 492 nm. MICs were defined as the lowest concentration that 248 
produced at least 50% reduction in metabolic activity of fungal biofilms compared to 249 
untreated control (Katragkou et al. 2014, Kovács et al. 2016, Nagy et al. 2019). Three 250 
independent experiments were performed for all isolates and the median of the three values 251 
were presented. 252 
 253 
2.10. In vitro interactions between farnesol and azoles for planktonic cells and biofilms 254 
A fractional inhibitory concentration index (FICI) was used to evaluate drug-drug interactions 255 
using a two-dimensional broth microdilution checkerboard assay both for planktonic and 256 
sessile cells (Meletiadis et al. 2005, Katragkou et al. 2015, Kovács et al. 2016). In the case of 257 
C. albicans, combinations were tested only for biofilms because planktonic isolates are 258 
generally susceptible to the tested azoles. The concentration ranges were as described above 259 
for MIC determination against planktonic cells and biofilms. The FICI expressed as 260 
ΣFIC=FICA+FICB=MICA
combination/MICA
alone+MICB
combination/MICB
alone, where MICA
alone and 261 
MICB
alone are the MIC values of compounds A and B used alone and MICA
combination and 262 
MICB
combination are the MICs of compounds A and B at the isoeffective combinations, 263 
respectively. FICI was defined as the lowest ΣFIC (Meletiadis et al. 2005, Katragkou et al. 264 
2015, Kovács et al. 2016). The MIC values of the drugs alone and of all isoeffective 265 
combinations were determined as the lowest drug concentrations showing at least 50% 266 
reduction of turbidity for planktonic, or at least 50% reduction in metabolic activity of biofilm 267 
compared to the untreated control cells. The interaction between azoles and farnesol was 268 
interpreted as synergistic when FICI was ≤0.5, as indifferent interaction when FICI was 269 
between >0.5 and 4 and as antagonism when FICI was >4 (Meletiadis et al. 2005, Katragkou 270 
et al. 2015, Kovács et al. 2016). 271 
 272 
2.11. In vivo experiments 273 
BALB/c immunocompromised female mice (21-23 g) (Charles River) were used to examine 274 
the effect of farnesol pre-exposure (75 M) and daily farnesol treatment (75 M) on virulence 275 
of C. auris and compared to C. albicans SC5314. The animals were maintained in accordance 276 
with the Guidelines for the Care and Use of Laboratory Animals. The experiments were 277 
approved by the Animal Care Committee of the University of Debrecen, Debrecen, Hungary 278 
(permission no. 12/2014 DEMÁB). Permanent immunosuppression was produced by 279 
intraperitoneal administration of 150 mg/kg cyclophosphamide 4 days prior to infection, 100 280 
mg/kg cyclophosphamide 1 day prior to infection, 100 mg/kg cyclophosphamide 2 days post-281 
infection and 100 mg/kg cyclophosphamide 5 days post-infection (Andes et al. 2010, Kovács 282 
et al. 2014). In accordance with our preliminary experiments, mice were challenged 283 
intravenously through the lateral tail vein; the infectious doses were 1 x 107 CFU/mouse and 8 284 
x 103 CFU/mouse in 0.2 mL volume for C. auris and C. albicans, respectively. Inoculum 285 
density was confirmed by plating serial dilutions on Sabouraud dextrose agar (Kovács et al. 286 
2014). Mice were divided into four groups (10 mice per group); i) untreated control mice; ii) 287 
inoculation with 24 hours-long farnesol pre-exposed (75 M) cells; iii) there was no farnesol 288 
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pre-exposure to fungal cells prior to infection, but 75 M daily farnesol treatment 289 
(corresponding to approximately 0.4 mg/kg) was started from 24 hours post-infection; iv) 24 290 
hours-long farnesol pre-exposure (75 M) to fungal cells prior to infection; afterwards, 75 M 291 
daily farnesol treatment was started at 24 hours post-infection. 292 
Farnesol treatments were administered intraperitoneally in a volume of 0.5 mL. Control mice 293 
were given 0.5 mL physiological saline intraperitoneally. At 6 days post-infection, mice were 294 
euthanized, and their kidneys were removed (Fakhim et al. 2018), weighed and homogenized 295 
aseptically. Fungal tissue burden was determined by quantitative culturing. Kidney tissue 296 
burden was analyzed using Kruskal-Wallis test with Dunn’s post-test (GraphPad Prism 6.05.). 297 
Significance was defined as p<0.05. 298 
 299 
2.12. Histology 300 
Kidneys of treated and untreated mice were subjected to histological investigations. 301 
Histopathological examination and histochemical staining were performed on routine 302 
formalin-fixed, paraffin-embedded mouse kidney tissues. Serial 4-m-thick sections were cut 303 
from paraffin blocks, and Periodic acid-Schiff (PAS) staining was performed (Pupim et al. 304 
2017, Kovács et al. 2019). 305 
306 
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3. Results 307 
 308 
3.1. Effect of farnesol on C. auris and C. albicans planktonic cell growth  309 
Significant decrease was observed in growth rate of C. auris for 12 hours in the presence of 310 
farnesol concentrations ranges from 50 to 300 M both in case of farnesol unexposed and pre-311 
exposed cells (p<0.001-0.05) (Figure 1A and B). At 24 hours, 100 and 300 M farnesol 312 
significantly decreased the viable cell count compared to untreated control in both 313 
experimental settings (p<0.01-0.001) (Figure 1A and B). Surprisingly, neither farnesol pre-314 
exposed nor unexposed C. albicans cells showed significant growth reduction at 24 hours 315 
(p>0.05) (Figure 1 C and D). 316 
 317 
3.2. Effects of farnesol on extracellular phospholipase and proteinase production of C. 318 
auris and C. albicans 319 
Farnesol treatment did not significantly influence the extracellular proteinase activity of either 320 
C. auris or C. albicans. The Pz values were 0.83 ± 0.04 and 0.82 ± 0.05 for C. auris untreated 321 
control and farnesol-exposed cells, respectively (p>0.05), as compared to 0.53 ± 0.003 and 322 
0.48 ± 0.02 with C. albicans untreated control and farnesol-exposed cells, respectively 323 
(p>0.05). Farnesol exposure resulted in significantly higher phospholipase activity for C. 324 
albicans (Pz values were 0.48 ± 0.04 and 0.42 ± 0.02 for untreated control and farnesol-325 
exposed cells, respectively (p<0.01); however, the Pz values were statistically comparable in 326 
case of C. auris (Pz values were 0.9 ± 0.04 and 0.89 ± 0.05 for untreated control and farnesol-327 
exposed cells, respectively (p>0.05). 328 
 329 
3.3. Farnesol-induced oxidative stress and stress response in C. auris and C. albicans. 330 
Farnesol caused a significantly higher reactive species production in C. auris compared with 331 
untreated control cells as presented in Table 1 (p<0.001). This farnesol-related higher reactive 332 
species level was associated with elevated superoxide dismutase (p<0.001) but statistically 333 
comparable catalase activity (p>0.05) (Table 1). Farnesol treatment did not result in 334 
significantly higher reactive species production in C. albicans (p>0.05), which is in line with 335 
the statistically comparable catalase and superoxide dismutase activity between farnesol 336 
exposed cells and untreated control (p>0.05) (Table 1). 337 
 338 
3.4. Effects of farnesol on biofilm forming ability and one-day-old biofilms of C. auris 339 
and C. albicans. 340 
(i) The effect of different farnesol concentrations on biofilm forming ability: All tested 341 
farnesol concentrations inhibited the metabolic activity of C. auris cells compared to control 342 
cells at first 8 hours (p<0.001-0.05); while, statistically comparable metabolic activities were 343 
measured at 24 hours (p>0.05) (Figure 2A). In contrast, all tested farnesol concentrations 344 
inhibited the metabolic activity of C. albicans cells compared to untreated control at 24 hours 345 
(Figure 2D). 346 
 (ii) Biofilm forming ability of cells pre-exposed with farnesol for 24-hours (75 M) prior to 347 
biofilm formation: Interestingly, we observed statistically significant differences in metabolic 348 
activity of C. auris cells only at 24 hours between 50 and 300 M (Figure 2B). In the case of 349 
C. albicans, statistically significant differences in metabolic activity between 50 and 300 M 350 
were first observed at 8 hours (Figure 2E), but the metabolic activity of cells treated by 351 
various concentrations was statistically comparable at 24 hours (Figure 2E). 352 
(iii) The effect of different farnesol concentrations against one-day-old biofilms: Between 2 353 
and 24 hours, 300 M farnesol produced a potent anti-biofilm effect against C. auris 354 
compared to control (Figure 2C). Interestingly, the low farnesol concentrations (10-50 M) 355 
increased the metabolic activity of C. albicans biofilms in the first 4 hours (Figure 2F). 356 
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However, the various farnesol treatments were statistically comparable against C. albicans at 357 
24 hours (Figure 2F). 358 
 359 
3.5. Susceptibility results for planktonic cells and biofilms 360 
For C. auris isolates, the planktonic MICs ranged from 4 to >32 mg/L, from 0.03 to 0.06 361 
mg/L, from 0.008 to 0.015 mg/L, from 0.015 to 0.03 mg/L and from 0.008 to 0.015 mg/L for 362 
fluconazole, voriconazole, isavuconazole, itraconazole and posaconazole, respectively. The 363 
susceptibility to fluconazole of isolate 10 was higher than the tentative fluconazole MIC 364 
breakpoint (>32 mg/L) while the other two strains were susceptible to fluconazole (CDC 365 
2020). In the case of planktonic C. albicans SC5314 reference strain, the median MIC values 366 
were 0.125 mg/L, 0.015 mg/L, 0.015 mg/L, 0.125 mg/L and 0.008 mg/L for fluconazole, 367 
voriconazole, isavuconazole, itraconazole and posaconazole, respectively. In case of biofilms, 368 
the median MIC values are shown in Table 2. 369 
 370 
3.6. Interactions between triazoles and farnesol by FICI 371 
Only indifferent interactions were detected for planktonic cells of C. auris (data not shown). 372 
The results of the triazole-farnesol interaction against one-day-old biofilms based on FICI are 373 
summarized in Table 2. Antagonism was never observed. Synergy between triazoles and 374 
farnesol was observed for all three C. auris isolates when grown in biofilm (FICI ranges from 375 
0.038 to 0.375) (Table 2). For the C. albicans SC5314 strain, the interaction pattern observed 376 
was very similar to C. auris; an indifferent interaction between an azole and farnesol was 377 
observed only in case of fluconazole, although, the FICI value calculated was very close to 378 
the synergy threshold (Table 2). 379 
 380 
3.7. In vivo experiments 381 
Results of the in vivo experiments are shown in Figure 3 and Figure 4 for C. auris and C. 382 
albicans, respectively. Seventy-five M farnesol treatment decreased the fungal kidney 383 
burden especially when farnesol pre-exposed C. auris cells were used as inoculum (Figure 3). 384 
With C. albicans, all experimental settings resulted in statistically comparable kidney fungal 385 
burdens compared to untreated control (Figure 4). The histopathology results observed were 386 
in line with the fungal burden-related results. C. auris produced single yeast cells and 387 
numerous budding yeast cells in untreated control mice. Although, inoculation by farnesol 388 
pre-exposed cells caused large number of aggregates in kidney tissue; the daily farnesol 389 
treatment markedly decreased the number of lesions (Figure 3). Both farnesol pre-exposure 390 
and daily farnesol treatment caused several extended fungal lesions in kidney tissue in the 391 
case of C. albicans infection (Figure 4), where single and budding yeast cells, pseudohyphae 392 
and hyphae were observed in all groups (Figure 4). 393 
394 
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4. Discussion 395 
Only a few classes of antifungal agents are available for the treatment of fungal infections; in 396 
addition, the antifungal drug discovery pipeline is slow and challenging, especially in case of 397 
the newly emerging difficult-to-treat species such as C. auris (Roemer and Crysan 2014, 398 
Scorzoni et al. 2017). Combination based therapeutic approaches have been proposed as 399 
alternatives in recent years to treat the C. auris infections. The combination of flucytosine 400 
with amphotericin B or micafungin may be relevant for the treatment of C. auris infections 401 
(Bidaud et al. 2019). Moreover, synergistic interactions were observed between micafungin 402 
and voriconazole (Fakhim et al. 2017). 403 
The investigations of alternative/adjuvant treatments focusing on fungal quorum-sensing 404 
molecules (e.g.: farnesol, tyrosol) have become an intensely researched area in recent years 405 
(Mehmood et al. 2019). Several in vitro and in vivo studies were performed to evaluate the 406 
antimicrobial effects of farnesol, which revealed that this compound may potentially serve as 407 
an alternative or adjuvant drug (Jabra-Rizk et al. 2006, Hisajima et al. 2008, Katragkou et al. 408 
2015, Kovács et al. 2016, Bozó et al. 2016, Nagy et al. 2019). Farnesol has a versatile effect 409 
at physiological concentrations, however, the most prominent of these is its ability to 410 
influence C. albicans morphology without markedly changing proliferation (Hornby 2001). It 411 
is noteworthy that farnesol not only affects C. albicans but has a remarkable inhibitory effect 412 
on other non-albicans species and moulds especially in supraphysiological concentrations 413 
(Jabra-Rizk et al. 2006; Henriques et al. 2007; Rossignol et al. 2007; Weber et al. 2010, 414 
Kovács et al. 2016). Our recent study reported that farnesol has a potential antifungal effect 415 
against C. auris biofilms (Nagy et al. 2019), nevertheless, the physiological processes 416 
underlying the observed antifungal activity of farnesol remain to be elucidated. 417 
Farnesol did not affect the growth rate of planktonic C. albicans; but caused significant 418 
reduction in growth rate in the case of C. auris. Moreover, farnesol inhibited the metabolic 419 
activity of one-day-old biofilms in the first 24 hours, a phenomenon clearly absent with C. 420 
albicans. The observed farnesol related effect in C. albicans is similar to those reported by 421 
Hornby et al. (2001). 422 
Farnesol has been suggested to modulate virulence, since it was shown to affect virulence-423 
associated phospholipase and aspartyl protease production in C. albicans. In this study, 424 
farnesol exposure resulted in significantly higher phospholipase activity for C. albicans, 425 
which is line with results reported by Fernandes et al. (2018). However, it did not enhance the 426 
production of these enzymes in experiments with C. auris. 427 
Farnesol was reported to cause a dose-dependent production of reactive species and could 428 
increase resistance to oxidative stress in C. albicans (Davis-Hanna et al. 2008, Deveau et al. 429 
2010, Giacometti et al. 2011), which is concordant with our results. However, farnesol 430 
treatment resulted in a significant increase of reactive species production in C. auris, resulting 431 
in an elevated level of superoxide dismutase but not catalase, demonstrating that farnesol 432 
might not contribute to protection against oxidative stress in C. auris. Such stress-related 433 
differences between C. albicans and C. auris were also observed previously with other 434 
stressor compounds. C. auris was more resistant to hydrogen-peroxide compared to C. 435 
albicans; but it was less tolerant to the superoxide-generating agent menadione and the tert-436 
butyl hydroperoxide, and moreover displayed significantly higher resistance to cationic stress 437 
imposed by either sodium chloride or calcium chloride compared to C. albicans (Day et al. 438 
2018).  439 
To date, catheter-associated infections caused by C. auris have been reported by several 440 
authors, which are attributable to the previously well-documented biofilm-forming ability of 441 
this species (Dewaele et al. 2018). Previous studies reported the frequency of central line 442 
infections by C. auris to be between 11% and 92%. (Taori et al 2019, Schelenz 2016, Lee 443 
2011). Although sessile communities show significantly higher resistance to the majority of 444 
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frequently used antifungals compared to planktonic susceptibilities (Kean and Ramage 2019), 445 
the efficacy of such antifungal agents can be enhanced using adjuvants such as farnesol (Nagy 446 
et al. 2019). A clear synergy between the tested triazoles and farnesol against C. auris 447 
biofilms was demonstrated, similarly to the combinations of echinocandins and farnesol 448 
(Nagy et al. 2019). Farnesol modulates the expression of genes linked to ergosterol 449 
biosynthesis, which may explain the synergy of this compound with triazoles (Yu et al. 2012).  450 
Although the in vitro effect of farnesol is well known especially against C. albicans, its in 451 
vivo role remains controversial and raises several questions. Navarathna et al. (2007) showed 452 
that exogenous farnesol (20 mM/mouse) can enhance the pathogenicity of C. albicans, 453 
increasing the mortality in a murine model of systemic candidiasis. In contrast, Hisajima et al. 454 
(2008) observed a farnesol-induced protective effect (at a dose 9 μM/mouse) in C. albicans-455 
associated oropharyngeal candidiasis. Although Bozó et al. (2016) revealed that farnesol 456 
alone is not protective in a murine vulvovaginitis model (150-300 μM/mouse), it did enhance 457 
the fluconazole activity against a fluconazole-resistant C. albicans isolate. In addition, 458 
chitosan nanoparticles containing miconazole and farnesol also inhibited fungal proliferation 459 
in a mouse vulvovaginitis model at ≥240 μM (Fernandes et al. 2019). To the best of our 460 
knowledge, there is no reported data concerning the in vivo activity of farnesol against non-461 
albicans Candida species. In this study, daily farnesol treatment decreased the C. auris fungal 462 
burden in mouse kidneys regardless of previous farnesol exposure of the inoculum. In 463 
addition, in the case of inocula pre-exposed to farnesol, the reduction of fungal cell numbers 464 
was statistically significant, which is concordant with our in vitro growth-related results. The 465 
antifungal activity observed may be explained by the elevated levels of reactive species 466 
previously measured in vitro, which could not be detected in equivalent experiments with C. 467 
albicans. Furthermore, the amphiphilic properties of farnesol allows for its integration into 468 
cell membranes, affecting membrane fluidity and integrity (Bringmann et al. 2000; Funari et 469 
al. 2005; Jabra-Rizk et al. 2006; Scheper et al. 2008). Farnesol was shown to affect cellular 470 
polarization and membrane permeability in C. parapsilosis and C. dubliniensis (Jabra-Rizk et 471 
al. 2006; Rossignol et al. 2007), which may also explain the observed antifungal effect in our 472 
study. However, it is noteworthy that the inoculation of farnesol pre-exposed cells without 473 
daily farnesol treatment resulted in a more virulent C. auris population and increased fungal 474 
burden. The 24-hours-long pre-exposure without further continuous treatment of farnesol may 475 
influence the expression of virulence determinants or membrane properties similar to 476 
fluconazole pre-treatment, which may explain the virulence enhancer effect reported 477 
previously (Navarathna et al. 2005). 478 
In conclusion, our results clearly demonstrate farnesol-related differences in physiology 479 
between C. albicans and C. auris. Based on our in vivo studies, farnesol has a remarkable 480 
therapeutic potential against C. auris; in addition, it reverses the well-documented resistance 481 
to newer triazoles reported for C. auris biofilms. However, further genome-wide gene 482 
expression analysis with C. auris is needed in order that each aspect of farnesol-related effects 483 
(e.g.: short-term exposure vs. long-term exposure) can be elucidated. 484 
 485 
 486 
487 
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Program of the Ministry of Human Capacities. 491 
 492 
 493 
6. Declaration of interest 494 
 495 
L. Majoros received conference travel grants from Cidara, MSD, Astellas and Pfizer. All 496 
other authors report no conflicts of interest. 497 
 498 
499 
 
 
 
13  
7. References 500 
 501 
Abastabar M, Haghani I, Ahangarkani F, et al. Candida auris otomycosis in Iran and review 502 
of recent literature. Mycoses. 2019;62(2):101–105. doi:10.1111/myc.12886 503 
 504 
Agustín MDR, Viceconte FR, Vela Gurovic MS, Costantino A, Brugnoni LI. Effect of 505 
quorum sensing molecules and natamycin on biofilms of Candida tropicalis and other yeasts 506 
isolated from industrial juice filtration membranes. J Appl Microbiol. 2019;126(6):1808–507 
1820. doi:10.1111/jam.14248 508 
 509 
Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison 510 
of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob 511 
Agents Chemother. 2010;54(6):2497–2506. doi:10.1128/AAC.01584-09 512 
 513 
Belkin A, Gazit Z, Keller N, et al. Candida auris Infection Leading to Nosocomial 514 
Transmission, Israel, 2017. Emerg Infect Dis. 2018;24(4):801–804. 515 
doi:10.3201/eid2404.171715 516 
 517 
Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into 518 
their cellular reduction. Biotechnol Annu Rev. 2005;11:127–152. doi:10.1016/S1387-519 
2656(05)11004-7 520 
 521 
Bidaud AL, Botterel F, Chowdhary A, Dannaoui E. In vitro antifungal combination of 522 
flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows 523 
no antagonism [published online ahead of print, 2019 Oct 7]. Antimicrob Agents Chemother. 524 
2019;63(12):e01393-19. 525 
 526 
Borman AM, Szekely A, Johnson EM. Comparative Pathogenicity of United Kingdom 527 
Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida 528 
Species. mSphere. 2016;1(4):e00189-16. Published 2016 Aug 18. 529 
doi:10.1128/mSphere.00189-16 530 
 531 
Borman AM, Szekely A, Johnson EM. Isolates of the emerging pathogen Candia auris 532 
present in the UK have several geographic origins. Med. Mycol. 2017; 55: 563-567. 533 
doi:10.1093/mmy/myw147 534 
 535 
Bozó A, Domán M, Majoros L, Kardos G, Varga I, Kovács R. The in vitro and in vivo 536 
efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a 537 
murine vulvovaginitis model. J Microbiol. 2016;54(11):753–760. doi:10.1007/s12275-016-538 
6298-y 539 
 540 
Casadevall A, Kontoyiannis DP, Robert V. On the Emergence of Candida auris: Climate 541 
Change, Azoles, Swamps, and Birds. mBio. 2019;10(4):e01397-19. Published 2019 Jul 23. 542 
doi:10.1128/mBio.01397-19 543 
 544 
Centers for Disease control and Prevention. Tracking Candida auris. 545 
https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. [Accessed 31 December 546 
2019]. 547 
 548 
Centers for Disease control and Prevention. Antifungal Susceptibility Testing and 549 
 
 
 
14  
Interpretation. https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html [Accessed 2 550 
January 2020] 551 
 552 
Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. Potential Fifth Clade of 553 
Candida auris, Iran, 2018. Emerg Infect Dis. 2019;25(9):1780–1781. 554 
doi:10.3201/eid2509.190686 555 
 556 
Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal 557 
susceptibility testing of yeasts. Approved standard, 3rd ed. M27-A3. CLSI, Wayne, PA, USA, 558 
2008. 559 
 560 
Davis-Hanna A, Piispanen AE, Stateva LI, Hogan DA. Farnesol and dodecanol effects on the 561 
Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis. Mol 562 
Microbiol. 2008;67(1):47–62. doi:10.1111/j.1365-2958.2007.06013.x 563 
 564 
Day AM, McNiff MM, da Silva Dantas A, Gow NAR, Quinn J. Hog1 Regulates Stress 565 
Tolerance and Virulence in the Emerging Fungal Pathogen Candida auris. mSphere. 566 
2018;3(5):e00506-18. Published 2018 Oct 24. doi:10.1128/mSphere.00506-18 567 
 568 
Deveau A, Piispanen AE, Jackson AA, Hogan DA. Farnesol induces hydrogen peroxide 569 
resistance in Candida albicans yeast by inhibiting the Ras-cyclic AMP signaling pathway. 570 
Eukaryot Cell. 2010;9(4):569–577. doi:10.1128/EC.00321-09 571 
 572 
Dewaele K, Frans J, Smismans A, Ho E, Tollens T, Lagrou K. First case of Candida auris 573 
infection in Belgium in a surgical patient from Kuwait [published online ahead of print, 2018 574 
Dec 4]. Acta Clin Belg. 2018;1–8. doi:10.1080/17843286.2018.1555114 575 
 576 
Dudiuk C, Berrio I, Leonardelli F, et al. Antifungal activity and killing kinetics of 577 
anidulafungin, caspofungin and amphotericin B against Candida auris. J Antimicrob 578 
Chemother. 2019;74(8):2295–2302. doi:10.1093/jac/dkz178 579 
 580 
European Centre for Disease Prevention and Control. Candida auris in healthcare settings 581 
Europe. https://ecdc.europa.eu/sites/portal/files/documents/RRA-Candida-auris-European-582 
Union-countries.pdf. [Accessed 5 November 2018]. 583 
 584 
Eyre DW, Sheppard AE, Madder H, et al. A Candida auris Outbreak and Its Control in an 585 
Intensive Care Setting. N Engl J Med. 2018;379(14):1322–1331. 586 
doi:10.1056/NEJMoa1714373 587 
 588 
Fakhim H, Chowdhary A, Prakash A, et al. In Vitro Interactions of Echinocandins with 589 
Triazoles against Multidrug-Resistant Candida auris. Antimicrob Agents Chemother. 590 
2017;61(11):e01056-17. Published 2017 Oct 24. doi:10.1128/AAC.01056-17 591 
 592 
Fakhim H, Vaezi A, Dannaoui E, et al. Comparative virulence of Candida auris with Candida 593 
haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses. 594 
2018;61(6):377–382. doi:10.1111/myc.12754 595 
 596 
Fernandes Costa A, Evangelista Araujo D, Santos Cabral M, et al. Development, 597 
characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing 598 
miconazole and farnesol for treatment of vulvovaginal candidiasis. Med Mycol. 599 
 
 
 
15  
2019;57(1):52–62. doi:10.1093/mmy/myx155 600 
 601 
Fernandes RA, Monteiro DR, Arias LS, Fernandes GL, Delbem ACB, Barbosa DB. Virulence 602 
Factors in Candida albicans and Streptococcus mutans Biofilms Mediated by Farnesol. Indian 603 
J Microbiol. 2018;58(2):138–145. doi:10.1007/s12088-018-0714-4 604 
 605 
Funari SS, Prades J, Escribá PV, Barceló F. Farnesol and geranylgeraniol modulate the 606 
structural properties of phosphatidylethanolamine model membranes. Mol Membr Biol. 607 
2005;22(4):303–311. doi:10.1080/09687860500135411 608 
 609 
Hawser S. Adhesion of different Candida spp. to plastic: XTT formazan determinations. J 610 
Med Vet Mycol. 1996;34(6):407–410. 611 
 612 
Henriques M, Martins M, Azeredo J, Oliveira R. Effect of farnesol on Candida dubliniensis 613 
morphogenesis. Lett Appl Microbiol. 2007;44(2):199–205. doi:10.1111/j.1472-614 
765X.2006.02044.x 615 
 616 
Hisajima T, Maruyama N, Tanabe Y, et al. Protective effects of farnesol against oral 617 
candidiasis in mice. Microbiol Immunol. 2008;52(7):327–333. doi:10.1111/j.1348-618 
0421.2008.00044.x 619 
 620 
Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida 621 
albicans is mediated by farnesol. Appl Environ Microbiol. 2001;67(7):2982–2992. 622 
doi:10.1128/AEM.67.7.2982-2992.2001 623 
 624 
Jabra-Rizk MA, Shirtliff M, James C, Meiller T. Effect of farnesol on Candida dubliniensis 625 
biofilm formation and fluconazole resistance. FEMS Yeast Res. 2006;6(7):1063–1073. 626 
doi:10.1111/j.1567-1364.2006.00121.x 627 
 628 
Jakab Á, Emri T, Sipos L, et al. Betamethasone augments the antifungal effect of menadione--629 
towards a novel anti-Candida albicans combination therapy. J Basic Microbiol. 630 
2015;55(8):973–981. doi:10.1002/jobm.201400903 631 
 632 
Jakab Á, Tóth Z, Nagy F, et al. Physiological and Transcriptional Responses of Candida 633 
parapsilosis to Exogenous Tyrosol. Appl Environ Microbiol. 2019;85(20):e01388-19. 634 
Published 2019 Oct 1. doi:10.1128/AEM.01388-19 635 
 636 
Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a Review of the Literature. Clin 637 
Microbiol Rev. 2017;31(1):e00029-17. Published 2017 Nov 15. doi:10.1128/CMR.00029-17 638 
 639 
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Table 1 Farnesol-induced oxidative stress response in C. auris and C. albicans 789 
 790 
 791 
 792 
Mean ± standard deviation values calculated from three independent experiments are 793 
presented. 794 
 795 
*** Significant differences at p< 0.001, as calculated by the paired Student’s t-test compared to 796 
untreated control and farnesol-treated cultures for C. auris. 797 
Oxidative stress related 
parameter 
Untreated cultures Farnesol-exposed cultures 
C. auris C. albicans C. auris C. albicans 
Catalase 
[kat (kg protein)-1] 
1.41 ± 0.03 0.60±0.07 1.56±0.09 0.48±0.07 
SOD [munit (mg protein)-1] 85.69±5.42 78.13±4.51 170.11±17.37*** 81.41±6.12 
DCF [nmol DCF (OD640)
-1] 3.96±0.89 9.69±1.01 23.54±4.51*** 11.45±1.15 
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Table 2 Minimum inhibitory concentration of fluconazole (FLU), voriconazole (VOR), 798 
itraconazole (ITRA), posaconazole (POSA) and isavuconazole (ISA) alone and in 799 
combination with farnesol (FAR) against C. auris (10, 12 and 27) and C. albicans SC5314 800 
biofilms (sMIC). Furthermore, in vitro interactions by fractional inhibitory concentration 801 
index (FICI) determination of fluconazole, voriconazole, itraconazole, posaconazole and 802 
isavuconazole in combination with farnesol against C. auris and C. albicans biofilms. Median 803 
MIC values and FICI values from three independent experiments are presented. 804 
 805 
 806 
 807 
 808 
 809 
 810 
 811 
 812 
 813 
 814 
 815 
 816 
 817 
 818 
 819 
 820 
 821 
 822 
 823 
 824 
 825 
 826 
 827 
 828 
 829 
 830 
 831 
 832 
 833 
 834 
 835 
 836 
 837 
 838 
a MIC is off-scale at >512 mg/l, 1024 mg/l (one dilution higher than the highest tested 839 
concentration) was used for analysis 840 
 841 
 842 
843 
Isolates  
Median sMIC values  Interaction analysis 
sMIC alone 
sMIC in 
combination Median 
FICI 
Type of interaction 
FLU 
(mg/L) 
FAR 
(M) 
FLU 
(mg/L) 
FAR 
(M) 
10  >512a 300 64 75 0.375 Synergy  
12 >512a 300 64 75 0.35 Synergy  
27 >512a 300 64 75 0.375 Synergy  
SC5314 >512a 150 64 75 0.56 Indifferent  
 
VOR 
(mg/L) 
FAR 
(M) 
VOR 
(mg/L) 
FAR 
(M) 
   
10 64 150 0.5 4.69 0.093 Synergy  
12 64 300 0.5 4.69 0.061 Synergy  
27 64 300 0.5 9.38 0.038 Synergy  
SC5314 16 150 1 4.69 0.09 Synergy  
 
ITRA 
(mg/L) 
FAR 
(M) 
ITRA 
(mg/L) 
FAR 
(M) 
   
10 16 300 0.5 4.69 0.155 Synergy  
12 32 300 0.5 9.375 0.140 Synergy  
27 16 300 0.5 9.375 0.123 Synergy  
SC5314 8 150 0.5 4.69 0.187 Synergy  
 
POSA 
(mg/L) 
FAR 
(M) 
POSA 
(mg/L) 
FAR 
(M) 
   
10 16 150 0.25 2.34 0.062 Synergy  
12 16 150 0.25 2.34 0.062 Synergy  
27 16 150 0.25 2.34 0.062 Synergy  
SC5314 2 150 0.25 4.69 0.28 Synergy  
 
ISA 
(mg/L) 
FAR 
(M) 
ISA 
(mg/L) 
FAR 
(M) 
   
10 4 300 0.125 9.38 0.091 Synergy  
12 8 300 0.125 18.75 0.062 Synergy  
27 4 300 0.125 9.38 0.091 Synergy  
SC5314 8 150 0.5 4.69 0.28 Synergy  
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Figure 1 844 
Time-kill curves of farnesol against C. auris (A and B) and C. albicans (C and D) isolates in 845 
RPMI-1640 for farnesol unexposed (A and C) and farnesol pre-exposed (B and D) cells (75 846 
M), respectively. Each timepoint represents mean ± SEM (standard error of mean) of cell 847 
count derived from isolates. 848 
 849 
Figure 2 850 
Metabolic activity changes over time in case of biofilm formation in the presence of given 851 
farnesol concentrations (10-300 M) for C. auris (A) and C. albicans (D), respectively. 852 
Metabolic activity changes over time in case of biofilm formation by farnesol pre-exposed 853 
cells (75 M) in the presence of given farnesol concentrations (10-300 M) for C. auris (B) 854 
and C. albicans (E), respectively. Metabolic activity changes over time for one-day-old 855 
preformed biofilms in the presence of given farnesol concentrations (10-300 M) for C. auris 856 
(C) and C. albicans (F), respectively. Each time-point represents mean ± SEM (standard error 857 
of mean) of metabolic activity of clinical isolates (three independent experiments per isolate).   858 
 859 
Figure 3 860 
The kidney burden of C. auris in a systemically infected mouse model. The bars represent the 861 
means ± SEM (standard error of mean) of kidney tissue burdens of BALB/c mice. Significant 862 
differences between CFU numbers were determined based on comparison with the untreated 863 
controls. Levels of significant differences are indicated (** p<0.01). Histological changes in 864 
kidney tissue from mice suffering from systemic candidiasis with or without farnesol 865 
treatment in the presence or absence of farnesol pre-exposure were examined by Periodic 866 
acid-Schiff staining. 867 
 868 
Figure 4 869 
The kidney burden of C. albicans in a systemically infected mouse model. The bars represent 870 
the means ± SEM (standard error of mean) of kidney tissue burdens of BALB/c mice. 871 
Significant differences between CFU numbers were determined based on comparison with the 872 
untreated controls. Histological changes in kidney tissue from mice suffering from systemic 873 
candidiasis with or without farnesol treatment in the presence or absence of farnesol pre-874 
exposure were examined by Periodic acid-Schiff staining. 875 
